GVOKE PFS: cost and payments to doctors
What Medicare Part D paid pharmacies for GVOKE PFS, and the payments that named it as the associated drug or biological under the Sunshine Act for program years 2019–2025.
Part D cost for GVOKE PFS formulations
Medicare reports GVOKE PFS under its specific formulations, which are priced separately.
- gvoke pfs 1 pack syringe$395per 30-day fill · 1,217 claims · Glucagon
- gvoke pfs 2 pack syringe$593per 30-day fill · 370 claims · Glucagon
Paid to pharmacies by Part D plans and patients — not your cost, and not paid to the prescriber. Is this wrong?
Was your doctor paid by Xeris Pharmaceuticals, Inc.?
Xeris Pharmaceuticals, Inc. reported the most payments naming GVOKE PFS. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $1.2M
- Providers
- 13,635
- Transactions
- 35,101
- Average per transaction
- $34
The per-transaction average — $34 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 13,635 providers the average total is $88, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | $1,205,730 | 100.0% |
Other products from Xeris Pharmaceuticals, Inc.
The company that reported the most payments naming GVOKE PFS also reports against these.
- GVOKE HYPOPEN$2,140,728
- RECORLEV$1,321,526
- KEVEYIS$240,086